27 related articles for article (PubMed ID: 22113345)
1. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
[TBL] [Abstract][Full Text] [Related]
2. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
[TBL] [Abstract][Full Text] [Related]
3. Identifying the translational gap in the evaluation of drug-induced QTc interval prolongation.
Chain AS; Dubois VF; Danhof M; Sturkenboom MC; Della Pasqua O;
Br J Clin Pharmacol; 2013 Nov; 76(5):708-24. PubMed ID: 23351036
[TBL] [Abstract][Full Text] [Related]
4. Giant T waves and QT interval prolongation associated with guanfacine toxicity.
Inoue F; Okazaki Y; Ichiba T; Chiba T; Namera A
Clin Toxicol (Phila); 2024 Apr; 62(4):269-271. PubMed ID: 38766906
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
[TBL] [Abstract][Full Text] [Related]
6. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
Lecka-Czernik B
IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
[TBL] [Abstract][Full Text] [Related]
7. Effects of high dose aleglitazar on renal function in patients with type 2 diabetes.
Herz M; Gaspari F; Perico N; Viberti G; Urbanowska T; Rabbia M; Wieczorek Kirk D
Int J Cardiol; 2011 Sep; 151(2):136-42. PubMed ID: 20837369
[TBL] [Abstract][Full Text] [Related]
8. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravenous zanamivir on cardiac repolarization.
Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
[TBL] [Abstract][Full Text] [Related]
10. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
11. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
12. No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Sturm S; Bentley D; Jordan P; Russell-Yarde F; Ruf T
J Cardiovasc Pharmacol; 2012 Mar; 59(3):288-97. PubMed ID: 22113345
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
Han CL; Qu CZ
J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
